The most serious complication of treatment with coagulation factor concentrates in patients with congenital hemophilia is development of alloantibodies against the deficient coagulation factor (F), namely, VIII (FVIII; hemophilia A) or IX (FIX; hemophilia B). [1] [2] [3] [4] [5] Indeed inhibitory alloantibodies, which develop in up to one-third of previously untreated patients with severe hemophilia A and up to 5 to 6% of patients with severe hemophilia B, neutralize the coagulant effect of factor replacement therapy, therefore requiring a shift toward treatments based on FVIII-and FIX-bypassing agents. [6] [7] [8] As a consequence, inhibitors preclude the access of persons with hemophilia to safe and effective standards of care, predisposing them to increased risk of morbidity and permanent disability which, ultimately, negatively influences their quality of life. 7 The management of hemophilia A patients with inhibitors is particularly challenging for physicians operating at hemophilia treatment centers (HTCs), as they are frequently forced to make critical decisions based on their own experience rather than on evidence-based data. 9 Due to the heavy social, health, and economic burden of inhibitors, 3 it is not surprising that several investigators have devoted their research in the last decade on understanding the pathogenic mechanisms of inhibitors to predict and, possibly, prevent their development. 9 However, while such investigation has been focused mainly on patients with hemophilia A and B, little is known pertaining to the inhibitors occurring in persons with the rarer congenital bleeding disorders due to defects of the other clotting factors. In this narrative review, we summarize the current knowledge on alloantibodies complicating replacement treatment in patients with inherited deficiency of coagulation FV, FVII, FXI, and FXIII. Alloantibodies occurring against von Willebrand factor in patients with von Willebrand disease and patients with Glanzmann's thrombasthenia and other inherited platelet disorders will not be discussed here, as these are the subjects of two other reviews in this issue of the journal.
Search Methods
We reviewed the medical literature for published studies on alloantibodies in patients with inherited bleeding disorders other than hemophilia A or hemophilia B. The MEDLINE electronic database was searched without temporal limits using English language restriction. The Medical Subject Heading and key words used were: "alloantibodies," "inhibitors," "inherited," "congenital," "bleeding disorders," "hemorrhagic disorders," "coagulation factors deficiency," "factor V (FV)," "factor XI (FXI)," "factor VII (FVII)," and "factor XIII (FXIII)." We also screened the reference lists of most relevant review articles for further studies not captured in our initial literature search. Search terms were also applied to abstracts from the latest international congresses on hemostasis and thrombosis and hematology. 
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FV deficiency is inherited in an autosomal recessive manner and has an estimated prevalence of approximately 1:1,000,000. [17] [18] [19] The first causative mutation in the F5 gene leading to a severe FV deficiency was discovered nearly 20 years ago 20 and there are currently more than 200 cases described so far with more than 100 DNA alterations reported, including nonsense and missense mutations, insertions, deletions, and splice-site mutations. 21 Two-thirds of all mutations causing FV deficiency are nonsense mutations in the FV gene. One-third of mutations causing FV deficiency introduce premature stop codons in the FV gene, either as nonsense mutations or as small out-of-frame insertions or deletions. Many new missense mutations, clustered in the A and C domains, have been described in recent years and now represent nearly 50% of all reported mutations. In most cases, these mutations affect secretion of FV, thus substantially reducing antigen levels (type I deficiency). 21 The fact that most patients carry a unique mutation which is not found in other FV-deficient patients confirms the remarkable allelic heterogeneity of this disease. 22 The initial identification of congenital FV deficiency may be based on the demonstration of the prolongation of both prothrombin time (PT) and activated partial thromboplastin time (aPTT), and the diagnosis by identification of reduced FV activity, usually determined by modified one-stage PT-based clotting assays. To distinguish qualitative from quantitative FV deficiency, a plasma FVantigen determined by immunoassay is required. 23 Congenital FV deficiency can be distinguished from acquired FV deficiency, in most cases due to FV autoantibodies occurring after exposure to bovine FV present in topical thrombin, 24 by noncorrection in PT and aPTT mixing studies in subjects without previous bleeding history. Frequent symptoms in patients with FV deficiency are epistaxis and menorrhagia, which occur in approximately 50% of cases. Other, less common symptoms, include hemarthroses and hematomas, which occur in approximately 25% of patients, whereas life-threatening episodes in the central nervous system and gastrointestinal tract are rare (6%).
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Pertaining to the treatment, there is no FV concentrate available, and FV is not present in significant amount in cryoprecipitate or prothrombin complex concentrates. 28 Thus, replacement therapy of FV is only achieved through fresh frozen plasma, preferably virus inactivated. [29] [30] [31] [32] [33] [34] Due to their relative content of FV, platelet transfusions have also been successfully used for the management of FV-deficient patients.
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Anti-FV Alloantibodies , and intravenous immunoglobulin (IVIG) failed to normalize the coagulation profiles. Exchange transfusion followed up by administrations of activated prothrombin complex and transfusions of fresh frozen plasma and platelet concentrates caused a temporary normalization of coagulation profile, enabling an insertion of a ventriculoperitoneal shunt for progressive hydrocephalus. The treatment was, however, complicated by thrombosis of the left brachial artery and the child finally died from another episode of intracranial hemorrhage 10 days thereafter. Divanon and colleagues 40 reported the case of a 19-year-old man with severe congenital FV deficiency and a high-titer (6 BU) inhibitor who was treated with single donor leukocyte-depleted platelet concentrate with a consequent anamnestic response (FV inhibitor rose up to 30 BU). Thus, the patient was successfully treated with recombinant activated factor VII (rFVIIa, bolus injections of 80 μg/kg at 3 hourly intervals on the first day, at 4 hourly intervals on the second day and then two daily boluses). Finally, Perez Botero and colleagues 41 described the case of a 67-year-old man with congenital FV deficiency and a high-titer FV inhibitor level with recurrent gastrointestinal bleeding due to arteriovenous malformations successfully treated with thalidomide after endoscopic, hemostatic (activated prothrombin complex concentrate), and hormonal (danazol) treatment failed. As immune tolerance induction (ITI) treatment was impracticable due to the high dose of fresh frozen plasma required, an alternative approach with high-dose corticosteroids and rituximab was attempted, resulting in inhibitor eradication. In summary, the data available on the characteristics of alloantibodies against infused FV in congenital FV deficiency are scanty (►Table 1), and most information regarding their management are derived from reports of acquired FV inhibitors. [43] [44] [45] Thus, for inhibitor eradication, various immunosuppressive agent-based protocols have been suggested.
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Pertaining to the treatment of bleeding, a large volume of fresh frozen plasma, necessary to overcome the inhibitor and produce an effective hemostatic effect, and platelet concentrates represent the mainstay of the treatment of bleeding in these complicated cases. In particular, transfusion of platelet concentrates should be considered as initial therapy, considering that FV in platelets, unlike that circulating in plasma, is protected from the neutralization of the antibody, being delivered directly to the site of injury. 46, 47 Also, the transfusion of platelets decreases the risk of circulatory overload associated with the transfusion of the large volume of plasma. In patients, refractory to repeated platelet transfusions, the administration of rFVIIa could be beneficial. 40 The main advantages of this recombinant hemostatic agent in such clinical setting include the efficacy being independent of the inhibitor titer and the lack of anamnestic response. In patients with a life-threatening bleeding tendency, an immediate reduction of the FV inhibitor titer by immunoadsorption or plasmapheresis with subsequent administration of fresh frozen plasma with or without platelet concentrates might be the best therapeutic approach.
Alloantibodies in Congenital FVII Deficiency Characteristics of Congenital FVII Deficiency
Factor VII is a 50 kDa vitamin K-dependent glycoprotein that circulates in plasma in two forms (99% as a single chain inactive form and 1% as an active two-chain form 
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The severity of symptoms of FVII deficiency is quite variable and reported to be poorly correlated with plasma levels. Some patients with severe deficiency do not bleed after major challenges of hemostasis. However, recent studies highlight that the most severe bleeding symptoms are reported in patients with FVII:C below 10% and that age and bleeding pattern at diagnosis may predict the bleeding tendency in such patients.
49,57,58 Life-or limb-endangering bleeding manifestations are relatively rare, the most frequent symptoms being epistaxis and menorrhagia. 59 The high incidence of central nervous system bleeding (16%) reported by Ragni and colleagues 48 in a series of 75 patients affected by FVII deficiency, was not confirmed by two subsequent studies. 53, 60 Thrombotic episodes (particularly venous thrombosis), have also been reported in 3 to 4% of patients with FVII deficiency, particularly in the presence of surgery and replacement treatment; however, spontaneous thrombosis may also occur.
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Current therapeutic options include fibrinolytic inhibitors, fresh frozen plasma, prothrombin complex concentrates, plasma-derived FVII concentrates and rFVIIa. 30 However, the very short half-life of FVII makes it difficult to use fresh frozen plasma without causing volume overload. Recombinant FVIIa has to be considered the optimal replacement therapy since it can be used at a very low dose (15-30 μg/kg).
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Anti-FVII Alloantibodies The type II Jewish mutation is a stop codon in exon 5, leading to undetectable FXI levels in homozygous individuals. The type III Jewish mutation is a missense mutation in exon 9 that causes a defective secretion of the protein from cells, but some FXI is ultimately produced so that measurable levels of FXI (at 10%) are present in these patients. Type II/III compound heterozygosity is the commonest cause of severe to moderate FXI deficiency in Ashkenazi Jews.
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In comparison with hemophilia A or B, bleeding manifestations in FXI deficiency are much less predictable, even in patients with severe deficiency. Bleeding is not related to FXI plasma levels but rather to the site of injury. Thus, the risk of bleeding is increased when at a site of injury with local high fibrinolytic activity (e.g., oral cavity after dental extraction or tonsillectomy, urogenital tract). 81 Patients with severe FXI deficiency are usually mildly affected and most bleeding manifestations are injury-related. Patients with low but detectable levels of FXI are also surprisingly mild bleeders, so that in these two groups clinical phenotypes are not strikingly different. 82 Women with FXI deficiency are prone to excessive bleeding during menstruation, but case series of women affected by severe FXI deficiency showed that 70% of pregnancies were uneventful, despite no prophylactic treatment.
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Treatment of congenital FXI deficiency is based upon the use of antifibrinolytic agents, fresh-frozen plasma, plasmaderived FXI concentrate and rFVIIa, but attention should be paid to reduce the risk of thrombotic complications (especially when FXI concentrates are employed), volume overload when fresh frozen plasma is used, and allergic reactions and development of inhibitors following FXI replacement therapy (see below). 73 As surgery or trauma can be associated with excessive and prolonged bleeding unless adequately treated, a careful evaluation of patients with severe FXI deficiency is recommended prior to surgery, as well as meticulous planning of the procedure and of the post-surgical course. FXI has a relatively long half-life (40-70 hours), so that the infusion of 15 to 20 mL/kg virus-inactivated fresh frozen plasma on alternate days should be sufficient to keep FIX at trough hemostatic levels of 15 to 20%.
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Anti-FXI Alloantibodies
A severe complication of replacement therapy in congenital FXI deficiency is the development of inhibitor to infused FXI. 86, 87 In a study conducted in 2003 by Salomon and colleagues on 188 Israeli patients with severe FXI deficiency, 7 of 21 patients (33%) homozygous for type II mutation developed inhibitors after exposure to plasma. 88 Characterization of these inhibitors revealed that they were all IgG alloantibodies and inhibited activation of FXI by thrombin or activated factor XII (FXIIa) and inhibited activation of FIX by exogenous FXIa. 88 Patients with FXI deficiency do not bleed spontaneously. Nevertheless, FXI inhibitors may increase surgical-or trauma-related bleeding and reduce responses to FXI replacement. 86 Thus, the presence of an inhibitor should be suspected (and investigated) when replacement therapy with fresh frozen plasma or FXI concentrate fails to correct a prolonged aPTT or when a patient continues to bleed despite appropriate treatment. In such cases, aPTT mixing studies and the modified Bethesda assay are helpful to detect and quantify the FXI inhibitor. 88 In addition, a periodical screening for inhibitor is mandatory in patients with severe FXI deficiency due to null mutations, especially if a surgical procedure is planned.
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Pertaining to the treatment of inhibitor patients, when the titer of inhibitor is low, the use of FXI concentrate may be hemostatically sufficient, although an anamnestic response is to be expected. 75 Since the first successful report by 
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Individuals with FXIII deficiency have an increased tendency to bleed. 104 Animal models of severe FXIII deficiency present with intrathoracic, intraperitoneal and subcutaneous hemorrhage. 105 In humans, bleeding from the umbilical stump in the first few days of life is common. Intracranial hemorrhage, ecchymoses, hematomas and prolonged bleeding following trauma are also characteristic. 106 Delayed wound healing was reported in approximately 30% of FXIII-deficient patients, while hemarthroses and bleeding into the muscles are less common than in hemophiliacs. 107 In a study using the largest group of patients with severe FXIII deficiency (93 Iranians) the most frequent mucosal tract bleeding symptom was bleeding in the oral cavity (lips, tongue, gum) followed by menorrhagia and epistaxis. 106 Twenty percent of patients in the reproductive age had intraperitoneal bleeding at the time of ovulation, while 50% of pregnant women had at least one miscarriage.
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The clinical severity of FXIII deficiency prompts regular prophylaxis. 98 This mode of treatment is facilitated by hemostatic levels of FXIII as low as 2 to 5%; given the very long plasma half-life of infused FXIII (11-14 days), replacement material can be infused at large intervals (20-30 days This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.
FXIII-A subunit deficiency; however, this reflects the majority of such cases of this congenital bleeding disorder.
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Anti-FXIII Alloantibodies
Besides severe acquired FXIII deficiency caused by an autoantibody against either of the FXIII subunits, 100 an anti-FXIII antibody may also develop in patients with inherited FXIII deficiency under replacement therapy. The incidence of such alloantibodies is unknown, although it seems to be a very rare event. Indeed, only seven cases of anti-FXIII-A alloantibodies have been reported so far in the literature,
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while there is only a single report on anti-FXIII-B alloantibodies. 120 The most recent report was that published by Penzes and colleagues in 2016. 119 The investigators characterized the anti-FXIII-A alloantibody, isolated from a patient with a severe FXIII-A deficiency and bleeding phenotype, demonstrating that it belonged to IgG class and exerted a multiple inhibitory effect on FXIII activation (interference with thrombin and Ca 2þ -induced FXIII activation) and activity (interference with the transglutaminase activity of activated FXIII).
119 Also, the alloantibody was responsible for an accelerated clearance of administered plasma-derived FXIII concentrate from the circulation. Attempts to eliminate the alloantibody through ITI treatment (Malmö protocol including cyclophosphamide, IVIG, and high-dose FXIII) resulted only in a transient improvement, and the patients died due to intracerebral hemorrhage. 119 Wada and colleagues 120 reported the case of a patient with severe congenital FXIII-B deficiency, whose mild bleeding phenotype was aggravated by the development of an anti-FXIII-B alloantibody. Finally, in a multicenter phase III trial in 41 patients with congenital FXIII-A subunit deficiency treated with recombinant FXIII-A 2 product, 4 patients developed transient, non-neutralizing, low-titer anti-FXIII antibodies.
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Conclusion
The development of inhibitory alloantibodies following replacement therapy in patients with inherited rare bleeding disorders is a very unusual adverse event, occurring much less frequently than reported in patients with congenital severe hemophilia A treated with FVIII concentrates, or even those with congenital severe hemophilia B treated with FIX concentrates. Nevertheless, the management of such rare inhibitors is perhaps even more challenging for caregivers of HTCs, especially considering that the published experience upon which to base their clinical practice is scanty. In this regard, while very little is known about treatments aiming to eliminate these inhibitors, rFVIIa seems to be the most universally acceptable therapeutic option for managing bleeding (except for FXIII deficiency, ►Table 1). The implementation of international registries aimed at recording additional inhibitor cases and improving our knowledge on their management is greatly welcomed.
